Amycretin is Novo Nordisk's investigational long-acting unimolecular co-agonist targeting both GLP-1 and amylin receptors. It is being developed in subcutaneous and oral formulations for weight management and type 2 diabetes. Based on early-phase clinical data, Novo Nordisk advanced both formulations into Phase 3 development.
Novo Nordisk struggles against Eli Lilly in the weight loss market as CagriSema underperforms Zepbound, though new candidate UBT251 shows promise with 19.7% weight loss in 24 weeks. The company expects sales to decline in 2026 despite oral Wegovy's success.
Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.
